Pacer Advisors
LGND icon

Pacer Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Pacer Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Sell
898
-419
-32% -$98.7K ﹤0.01% 1695
2026
Q1 		$263K Buy
+1,317
New +$261K ﹤0.01% 1677
2025
Q4 		– Sell
-1,837
Closed -$325K – 3840
2025
Q3 		$325K Buy
1,837
+754
+70% +$112K ﹤0.01% 1812
2025
Q2 		$123K Sell
1,083
-1,436
-57% -$153K ﹤0.01% 2220
2025
Q1 		$265K Buy
+2,519
New +$285K ﹤0.01% 1679
2024
Q1 		– Sell
-325,727
Closed -$23.3M – 3702
2023
Q4 		$23.3M Buy
325,727
+121,049
+59% +$7.14M 0.07% 276
2023
Q3 		$12.3M Buy
204,678
+67,928
+50% +$4.47M 0.05% 295
2023
Q2 		$9.86M Sell
136,750
-16,793
-11% -$1.26M 0.04% 381
2023
Q1 		$11.3M Buy
153,543
+41,438
+37% +$2.95M 0.05% 361
2022
Q4 		$7.49M Buy
+112,105
New +$7.29M 0.04% 373
2022
Q3 		– Sell
-93,259
Closed -$5.19M – 2176
2022
Q2 		$5.19M Buy
+93,259
New +$5.29M 0.04% 362
2021
Q3 		– Sell
-2,812
Closed -$230K – 1449
2021
Q2 		$230K Sell
2,812
-796
-22% -$66.2K ﹤0.01% 1282
2021
Q1 		$343K Sell
3,608
-1,525
-30% -$144K 0.01% 1190
2020
Q4 		$318K Sell
5,133
-2,544
-33% -$145K 0.01% 1142
2020
Q3 		$456K Buy
+7,677
New +$524K 0.01% 1014
2020
Q1 		– Sell
-9,565
Closed -$622K – 911
2019
Q4 		$622K Sell
9,565
-2,653
-22% -$177K 0.03% 721
2019
Q3 		$759K Sell
12,218
-941
-7% -$59.1K 0.02% 900
2019
Q2 		$937K Buy
+13,159
New +$969K 0.02% 827
2018
Q4 		– Sell
-2,148
Closed -$368K – 821
2018
Q3 		$368K Buy
+2,148
New +$324K 0.01% 917
2018
Q1 		– Sell
-802
Closed -$68K – 1089
2017
Q4 		$68K Buy
+802
New +$69.5K ﹤0.01% 989

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's LGND Position: Q2 2026 in Review

Pacer Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 32% in Q2 2026, selling an estimated $98.7K and leaving 898 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #1695.

Pacer Advisors first reported a position in LGND in Q4 2017 and has held it in 20 quarters since. The position peaked at $23.3M in Q4 2023. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Pacer Advisors held 898 shares of Ligand Pharmaceuticals worth $284K as of Q2 2026.
  • Pacer Advisors sold 419 Ligand Pharmaceuticals shares in Q2 2026, an estimated $98.7K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1695 holding.
  • Pacer Advisors first reported a position in Ligand Pharmaceuticals in Q4 2017 and has held it in 20 quarters since.
  • Pacer Advisors's Ligand Pharmaceuticals position peaked at $23.3M in Q4 2023.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.